A PET scan of lymph nodes reveals whether those small, bean-shaped glands are metabolically active in a way that suggests cancer, infection, or inflammation. The scan works by tracking how much of a radioactive sugar tracer your cells absorb: cancer cells, which burn through glucose faster than normal tissue, tend to light up brightly. But “lighting up” is not the same as a confirmed diagnosis, and that gap between what the scan shows and what it means is where most of the anxiety and confusion live.
How the Scan Detects Abnormal Lymph Nodes
The tracer used in most PET scans is a modified glucose molecule tagged with a tiny amount of radioactive fluorine. After it’s injected into your bloodstream, it circulates for about an hour while your cells take it up. Cells that are more metabolically active, including most cancer cells, absorb more of it. The PET scanner then detects the radiation emitted from these hot spots and maps them onto a three-dimensional image of your body.
Nearly all modern PET scans are combined with a CT scan done at the same time on the same machine. The CT provides a detailed anatomical picture, while the PET shows metabolic activity. When you overlay the two, you get a precise map: not just “something is active” but “something is active right here, in this specific lymph node, next to this blood vessel.” This combination significantly improves accuracy over either scan alone. Compared with imaging that relies only on size and shape, PET/CT adds functional data that increases the ability to distinguish cancerous lymph nodes from normal ones.1European Journal of Radiology. Lymph node staging with dual-modality PET/CT: Enhancing the diagnostic accuracy in oncology In esophageal cancer, for instance, PET/CT reached about 94% sensitivity for detecting involved lymph nodes, compared with roughly 82% for PET images read without the CT component.2Journal of Nuclear Medicine. Additional Value of PET/CT over PET in Assessment of Locoregional Lymph Nodes in Thoracic Esophageal Squamous Cell Cancer
What Doctors Look for on the Images
When a radiologist or nuclear medicine physician reads your PET scan, they’re looking at how intensely each lymph node absorbs the tracer. That intensity is expressed as a number called the SUV, or standardized uptake value. A higher SUV generally means higher metabolic activity, which raises suspicion for cancer. In practice, an SUV around 2.5 is often used as a rough threshold to separate concerning nodes from probably-benign ones. One study of lung cancer patients found that using 2.5 as the cutoff produced a very high negative predictive value of 96%, meaning that when lymph nodes fell below that threshold, cancer was almost always absent.3Journal of Nuclear Medicine. 18F-FDG PET for Mediastinal Staging of Lung Cancer: Which SUV Threshold Makes Sense?
The picture gets muddier at higher values. A node with an SUV of 6 or 8 could be cancer, but it could also be inflamed or reactive. One study of chest lymph nodes in lung cancer patients found that benign nodes had SUV values ranging from 2.3 all the way up to 11.8, while malignant nodes ranged from 2.4 to 34. Raising the cutoff to about 6.2 improved the balance between catching true cancers and avoiding false alarms, yielding roughly 87% sensitivity and 70% specificity.4PubMed Central. Evaluation of mediastinal lymph nodes using F-FDG PET-CT scan and its histopathologic correlation In short, experienced readers don’t rely on a single number. They weigh the SUV alongside the node’s size, shape, location, and your clinical history. For less experienced interpreters, the SUV can serve as a useful secondary aid, but it’s not a binary cancer-or-not switch.
How PET Scans Guide Lymphoma Treatment Decisions
If you’re being evaluated or treated for lymphoma, PET scans play an especially central role. They’re used at nearly every stage: initial staging to see how far the disease has spread, mid-treatment checks to see if chemotherapy is working, and post-treatment scans to confirm remission or detect relapse.5PubMed Central. Current status of PET/CT in the diagnosis and follow up of lymphomas
For lymphoma response assessment, doctors use a five-point rating system called the Deauville score rather than relying on raw SUV numbers. The scale compares how much tracer the lymph node takes up relative to the liver and the blood pool (a large vein used as an internal reference). A score of 1 means no uptake above background, essentially a clean scan. A score of 2 or 3 indicates uptake at or slightly above liver level, which is generally considered a good response. Scores of 4 or 5 indicate uptake well above liver level, raising concern that disease is still active or has returned.
The Deauville score has become the standard for deciding whether treatment is working. In one validation study of Hodgkin lymphoma patients, over 95% of scans scored 1 through 3 matched a favorable clinical course, while patients scored 4 or 5 who stayed on the same treatment regimen often showed disease progression on subsequent scans.6PubMed Central. Validation of Deauville Score for Response Evaluation in Hodgkin’s Lymphoma A positive Deauville score at the interim check has also been linked to worse progression-free survival.7Journal of Clinical Medicine. The Comparative Prognostic Value of the Interim PET Deauville Score and ΔSUVmax in Classical Hodgkin Lymphoma: A Real-World Study of Imaging and Inflammatory Markers Incorporating size changes alongside the Deauville score can further improve specificity in certain scoring frameworks.8PubMed Central. FDG PET/CT Response Assessment Criteria for Patients with Hodgkin’s and Non-Hodgkin’s Lymphoma at End of Therapy: A Multiparametric Approach
Why a Bright Lymph Node Does Not Always Mean Cancer
The radioactive sugar tracer is not cancer-specific. Any cell that is metabolically revved up will grab it, and immune cells fighting an infection or responding to inflammation are very active. This is the single biggest source of false positives on PET scans. Tuberculosis, fungal infections, sarcoidosis, and even surgical inflammation can all cause lymph nodes to light up convincingly.9PubMed Central. False positive and false negative FDG-PET scans in various thoracic diseases Sites of infection and inflammation are a well-documented source of misdiagnosis on oncology PET scans and require careful interpretation.10Biomedicine & Pharmacotherapy. The impact of infection and inflammation in oncologic 18F-FDG PET/CT imaging
One especially common real-world scenario involves recent vaccinations. COVID-19 vaccines, for example, frequently trigger tracer uptake in the armpit lymph nodes on the injection side. In one study of patients who had recently been vaccinated, 85% showed axillary or deltoid tracer uptake related to the vaccine, with a median interval of only 11 days between the shot and the scan.11PubMed Central. COVID-19 vaccine related hypermetabolic lymph nodes on PET/CT: Implications of inflammatory findings in cancer imaging HPV vaccines produce a similar effect: all recipients in one study showed lymph node activity on the same side as the injection, and some showed activity on both sides, persisting for over a month.12PubMed Central. Lymph Node Activation by PET/CT Following Vaccination with Licensed Vaccines for Human Papillomaviruses This is why your care team will ask about recent vaccinations before scheduling a PET scan, and why many centers recommend waiting a few weeks after a vaccine when possible.
Surgery is another culprit. Reactive lymph nodes that swell after an operation can mimic metastatic spread on a PET scan, potentially leading to unnecessary worry or additional procedures.13PubMed Central. Postoperative reactive lymphadenitis: A potential cause of false-positive FDG PET/CT In one study of lung cancer patients, only 14 out of 100 lymph node stations that were PET-positive turned out to be truly cancerous on biopsy. The rest were attributed to anthracosis (coal dust deposits), reactive inflammation, granulomatous disease, or silicosis.14PubMed Central. The correlation of SUVmax with pathological characteristics of primary tumor and the value of Tumor/ Lymph node SUVmax ratio for predicting metastasis to lymph nodes in resected NSCLC patients If you live in an area with endemic fungal infections or have a history of occupational dust exposure, these false-positive rates may be even higher for you.
When the Scan Misses Cancer That Is Actually There
The flip side of false positives is false negatives: cancer that exists but doesn’t show up. The main culprit is size. Very small deposits of cancer, called micrometastases, simply don’t contain enough metabolically active cells to register above background noise. In lung cancer patients, PET scanning couldn’t detect any metastatic deposits smaller than 4 mm and caught nearly all deposits 5 mm or larger.15The Journal of Thoracic and Cardiovascular Surgery. The size of metastatic foci and lymph nodes yielding false-negative and false-positive lymph node staging with positron emission tomography in patients with lung cancer For melanoma, PET reliably detected lymph node deposits above roughly 80 cubic millimeters in volume, but sensitivity dropped sharply below that.16PubMed. FDG-PET sensitivity for melanoma lymph node metastases is dependent on tumor volume
This size limitation is clinically important. It means that for certain cancers, especially melanoma and breast cancer at an early stage, a clean PET scan of the lymph nodes is not sufficient to rule out microscopic spread. That’s why sentinel lymph node biopsy, where a surgeon removes the first node that drains the tumor and examines it under a microscope, remains the gold standard for local lymph node staging in these diseases. In melanoma, sentinel node biopsy is considered superior to PET for detecting lymph node involvement in patients with intermediate-risk disease.17PubMed. PET vs sentinel lymph node biopsy for staging melanoma: a patient intervention, comparison, outcome analysis Similarly, in breast cancer, PET detected only about 37% of axillary lymph node metastases in one comparative study, though its specificity was high at 96%.18Annals of Oncology. A comparative study on the value of FDG-PET and sentinel node biopsy to identify occult axillary metastases In other words, when PET says a node is positive, it’s usually right. But when it says a node is clean, the cancer may simply be too small to see.
Beyond the Standard Sugar Tracer
The standard tracer, FDG, works well for many cancers but isn’t ideal for all of them. Some tumors, particularly prostate cancer, don’t consume glucose aggressively enough to show up reliably on FDG-PET. That limitation has driven the development of alternative tracers tailored to specific cancer types.
The most widely adopted example is PSMA PET, which targets a protein found on the surface of most prostate cancer cells. PSMA PET/CT has improved the detection of both local and distant prostate cancer spread compared to conventional imaging.19PubMed Central. PSMA PET-CT in the Diagnosis and Staging of Prostate Cancer It plays a growing role in initial staging, detecting recurrence after surgery, and guiding targeted radiation to specific metastatic sites. For lymph node metastases specifically, one study found PSMA PET sensitivity around 53% overall, rising to 67% when surgeons removed a larger number of nodes for comparison, with specificity around 86-88%.20PubMed. The accuracy of (68)Ga-PSMA PET/CT in primary lymph node staging in high-risk prostate cancer Those sensitivity numbers are modest, which underscores that even newer tracers have size-related blind spots similar to FDG. Still, PSMA PET has largely replaced older imaging approaches for prostate cancer staging in major treatment centers.
What to Expect on the Day of the Scan
If you’ve never had a PET scan, the process may seem intimidating, but the procedure itself is painless. You’ll typically be asked to fast for four to six hours beforehand. The fasting matters because the tracer competes with the glucose already in your bloodstream. Elevated blood sugar can affect how the tracer distributes through your body, particularly in the brain and liver, though the effect on tumor uptake itself appears to be limited except at very high glucose levels (above about 200 mg/dL).21PubMed. Effect of blood glucose level on standardized uptake value (SUV) in (18)F- FDG PET-scan: a systematic review and meta-analysis of 20,807 individual SUV measurements If you have diabetes, your team will give you specific instructions about managing your medications and blood sugar before the appointment.
After the tracer injection, you’ll sit quietly for about 45 to 60 minutes while the tracer circulates and is taken up by your cells. Talking, chewing gum, or moving around during this time can cause muscles and salivary glands to absorb more tracer, which can create confusing hot spots on the images. The scan itself usually takes 20 to 30 minutes, during which you lie still on a narrow table that slides through the scanner. You won’t feel anything from the scanning process. The total time from arrival to departure is usually around two to three hours.
Anxiety is common and worth acknowledging. A study of oncology patients undergoing PET/CT found that pre-procedure anxiety levels averaged about 6.4 on a 10-point scale, dropping modestly to about 5.7 afterward. Knowing what the scan involves ahead of time appears to help, and speaking with your technologist about each step as it happens can take some of the edge off.
Radiation Exposure in Perspective
Because a PET/CT involves both a radioactive tracer and an X-ray CT scan, you receive radiation from two sources. The total effective dose from a standard PET/CT is typically in the range of 10 to 25 millisieverts, depending on the tracer dose and how the CT component is configured. For context, that’s roughly equivalent to a few years of natural background radiation, and it falls within the range of other common medical imaging procedures that use radiation. The tracer is short-lived: the fluorine-18 used in standard FDG PET decays by half in about two hours, so most of the radioactivity is gone from your body within a day. You’ll be advised to drink plenty of water afterward to help flush the remaining tracer through your kidneys.
For people who need repeated PET scans over the course of treatment, cumulative radiation dose is a reasonable concern to raise with your oncologist. Many centers now use lower-dose CT protocols for the CT portion of a PET/CT when high-resolution anatomical detail isn’t the primary goal, which can meaningfully reduce the total dose per scan.
Insurance and Prior Authorization
PET scans are expensive, and most insurers require prior authorization before they’ll cover one. Your doctor’s office typically handles this process, but delays can occur, and denials are not uncommon, particularly for indications that insurers consider outside established guidelines. Patients who are denied coverage sometimes face a choice between paying out of pocket, pursuing an appeal, or accepting an alternative imaging approach that may be less informative.22PubMed. Impact of Prior Authorization on Patient Access to Cancer Care If you receive a denial, ask your oncologist whether an appeal is worthwhile. Many initial denials are overturned when additional clinical documentation is submitted. In the United States, Medicare generally covers PET scans for initial staging and restaging of most solid tumors and lymphomas, but coverage for treatment monitoring or surveillance scans varies by cancer type and clinical situation.
Artificial Intelligence and the Future of PET Interpretation
Reading PET scans is subjective enough that two experienced physicians looking at the same images will sometimes disagree about which lymph nodes are involved. That variability has motivated research into AI tools that can flag suspicious nodes automatically. In lymphoma, one neural-network-based system detected involved lymph nodes with about 85% sensitivity at a rate of roughly four false-positive findings per patient, a performance level the researchers described as approaching the differences between two physicians’ own annotations.23PubMed Central. Convolutional Neural Networks for Automated PET/CT Detection of Diseased Lymph Node Burden in Patients with Lymphoma
For PSMA PET scans in prostate cancer, AI models have shown sensitivity comparable to or slightly above that of human readers for detecting pelvic lymph node metastases, with one freely available tool achieving 82% sensitivity versus an average of 77% for the physicians it was compared against.24PubMed Central. Freely available artificial intelligence for pelvic lymph node metastases in PSMA PET-CT that performs on par with nuclear medicine physicians A broader systematic review found that AI could detect lymph node involvement and metastatic disease on PSMA PET scans with accuracy as high as 98% by some measures, though sensitivity varied widely depending on the specific model and dataset.25PubMed Central. A Systematic Review on Artificial Intelligence Evaluating Metastatic Prostatic Cancer and Lymph Nodes on PSMA PET Scans
These tools are not replacing radiologists or nuclear medicine doctors yet. Their current role is more like a second set of eyes: flagging nodes that a human might overlook, particularly in scans with dozens of nodes to evaluate. As these systems mature, they could help standardize interpretation, reduce the variability between readers, and speed up turnaround times for results. For patients, the practical upside would be more consistent and potentially faster reporting, especially at centers where specialist availability is limited.